SMARCA4/BRG1 TR-FRET Assay Kit
975 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 421 - 40341
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 384 rxns.
40342
SMARCA2 TR-FRET Assay Kit
The SMARCA2 TR-FRET Assay Kit is designed to measure the inhibition of SMARCA2 (BRM) binding to its substrate in a homogeneous 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing terbium-labeled donor, dye-labeled acceptor, SMARCA2, substrate, and an inhibitor is incubated for 120 minutes. Then, the fluorescence intensity is measured using a fluorescence reader.
975 €
32609
SMARCA4/BRG1 Inhibitor Screening Assay Kit
The BRG1 Inhibitor Screening Assay Kit is designed to measure the inhibition of BRG1 binding to its substrate. The key to the BRG1 Inhibitor Screening Assay Kit is the specific binding of the BRG1 bromodomain to an acetylated histone substrate. With this kit, only three simple steps on a microtiter plate are required. First, a sample containing BRG1 and an inhibitor of choice is incubated with the biotinylated substrate. Next, acceptor beads are added, then donor beads, followed by reading the Alpha-counts.
915 €
31102
SMARCA4 (BRG1), His-tag
Human BRG1, also known as SMARCA4, GenBank Accession No. NM_1128849, a.a. 1480 - 1603 corresponding to single bromodomain with N-terminal His-tag, MW = 15.5 kDa, expressed in an E. coli expression system.
607.5 €
79786
c-CBL TR-FRET Assay Kit
Casitas B lineage lymphoma (c-Cbl) is a multifunctional protein with ubiquitin E3 ligase activity capable of degrading diverse sets of proteins. c-Cbl is a ubiquitously expressed mammalian protein that plays a vital role in fundamental cellular functions including cell survival, migration, and proliferation. Recent evidence suggests a critical role for c-Cbl in angiogenesis and human solid organ tumors, making it a potential drug target in cancer immunotherapy. The c-CBL TR-FRET Assay Kit is designed to measure c-CBL auto-ubiquitination activity in a homogeneous 384 reaction format. It utilizes Biotin-labeled Ubiquitin and a terbium-labeled anti-c-CBL antibody to complete the TR-FRET pairing. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications.
3007.5 €
32613
BRD4 (BD1) TR-FRET Assay Kit
The BRD4 (BD1) TR-FRET Assay Kit is designed to measure the_x000D_inhibition of BRD4 (BD1) binding to its substrate in a homogeneous 384 reaction format._x000D_This FRET-based assay requires no time-consuming washing steps, making it especially_x000D_suitable for high throughput screening applications. The assay procedure is_x000D_straightforward and simple; a sample containing terbium-labeled donor, dye-labeled_x000D_acceptor, BRD4, substrate, and an inhibitor is incubated for sixty minutes. Then, the_x000D_fluorescence intensity is measured using a fluorescence reader.
1012.5 €
32617
BRD4 (BD2) TR-FRET Assay Kit
The BRD4 (BD2) TR-FRET Assay Kit is designed to measure the inhibition of BRD4_x000D_(BD2) binding to its substrate in a homogeneous 384 reaction format. This FRET-based_x000D_assay requires no time-consuming washing steps, making it especially suitable for high_x000D_throughput screening applications. The assay procedure is straightforward and simple; a_x000D_sample containing terbium-labeled donor, dye-labeled acceptor, BRD4, substrate, and_x000D_an inhibitor is incubated for sixty minutes. Then, the fluorescence intensity is measured_x000D_using a fluorescence reader.
1012.5 €
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Biologiska läkemedel – Modernitet inom farmaci
1 August 2025
By: Author , 2 Comment
Icke-steroida antiinflammatoriska läkemedel – viktig information om populära läkemedel
22 July 2025